Key Takeaways Eli Lilly will acquire Verve for roughly $1 billionVerve is developing a one-time gene-editing treatment for ...

With backers such as Regeneron’s venture arm, Actio Biosciences is working on medicines that counter a wide range of ...

Global shares were mostly higher Wednesday and oil prices slipped as investors awaited a decision on interest rates by the ...

Asian shares are mixed and oil prices have dropped Wednesday as investors calmed from the jitters of conflict in the Middle ...

Eli Lilly's $1.3B acquisition of Verve Therapeutics caused a sharp rally, but with shares above the buyout price, I recommend ...

Scholar Rock (NASDAQ:SRRK) announced Wednesday that its lead candidate, apitegromab, in combination with Eli Lilly’s ...

Eli Lilly has announced that it will be acquiring Verve Therapeutics in a deal worth approximately $1.3bn, marking a ...